Cas:178984-50-4 4-Chloro-7-ethoxyquinoline manufacturer & supplier

We serve Chemical Name:4-Chloro-7-ethoxyquinoline CAS:178984-50-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

4-Chloro-7-ethoxyquinoline

Chemical Name:4-Chloro-7-ethoxyquinoline
CAS.NO:178984-50-4
Synonyms:7-Aethoxy-4-chlor-chinolin;7-ethoxy-4-chloro-quinoline
Molecular Formula:C11H10ClNO
Molecular Weight:207.65600
HS Code:

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:22.12000
Exact Mass:207.04500
LogP:3.28690

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:


Contact us for information like 7-Aethoxy-4-chlor-chinolin chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,7-ethoxy-4-chloro-quinoline physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,7-ethoxy-4-chloro-quinoline Use and application,7-ethoxy-4-chloro-quinoline technical grade,usp/ep/jp grade.


Related News: A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 4-Chloro-7-ethoxyquinoline manufacturer The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed. 4-Chloro-7-ethoxyquinoline supplier A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA��s concerns. 4-Chloro-7-ethoxyquinoline vendor Fate Therapeutics�� iPSC product platform is supported by an intellectual property portfolio of over 250 issued patents and 150 pending patent applications. 4-Chloro-7-ethoxyquinoline factory The company-backed investigation was based on interviews with more than 100 people, the May 20 memo to Lilly employees said. However, the memo did not respond to all concerns employees raised in their April complaint, which Reuters reviewed.